{
    "nctId": "NCT01965522",
    "briefTitle": "Anti-proliferative Effects of Vitamin D and Melatonin in Breast Cancer",
    "officialTitle": "Anti-proliferative Effects of Vitamin D and Melatonin in Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Early Stage Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Ki67",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Woman with histologically confirmed invasive breast cancer (ductal, lobular, or mixed)\n* Planned to undergo definitive surgery, either lumpectomy or mastectomy in 3 or more weeks\n\nExclusion Criteria:\n\n* Less than 18 years of age\n* Stage IIIB or IV disease\n* Inoperable locally advanced or metastatic breast cancer\n* Neoadjuvant chemotherapy is intended\n* Currently taking vitamin D supplements\n* Currently taking melatonin supplements\n* Previously taking vitamin D or melatonin supplements within the last 3 months\n* Currently taking a multivitamin and not willing to discontinue for the duration of the study\n* Hyperparathyroid disease or other calcium disturbance in the past five years\n* Active renal stones in the last six months\n* Renal failure (creatinine \\> 190 mmol/L)\n* Hypercalcemia (serum calcium \\> 2.6 mmol/L)\n* Known pregnancy\n* Participation in another clinical trial where the patient receives any other investigational product\n* Unwilling or unable to provide informed consent",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}